Cover Image
市場調查報告書

類鐸受體4:開發中產品分析

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 365746
出版日期 內容資訊 英文 115 Pages
訂單完成後即時交付
價格
Back to Top
類鐸受體4:開發中產品分析 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016
出版日期: 2016年12月28日 內容資訊: 英文 115 Pages
簡介

本報告提供以類鐸受體4為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Batu Biologics, Inc.
  • BioLineRx, Ltd.
  • Biomedica Management Corporation
  • Eisai
  • eTheRNA Immunotherapies NV
  • Formune S.L.
  • GlaxoSmithKline Plc
  • Harbor Therapeutics, Inc.
  • Immune Design Corp.
  • Immunovo BV
  • kyorin製藥
  • NovImmune SA
  • Reliance Life Sciences Pvt. Ltd.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • Vascular Biogenics Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0746TDB

Summary

Global Markets Direct's, 'Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) Overview
  • Therapeutics Development
    • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Stage of Development
    • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Therapy Area
    • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Indication
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Companies
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Universities/Institutes
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
    • Batu Biologics Inc
    • BioLineRx Ltd
    • Biomedica Management Corp
    • eTheRNA Immunotherapies NV
    • Formune SL
    • GlaxoSmithKline Plc
    • Harbor Therapeutics Inc
    • Immune Design Corp
    • Immunovo BV
    • Kyorin Pharmaceutical Co Ltd
    • NovImmune SA
    • Reliance Life Sciences Pvt Ltd
    • TaiwanJ Pharmaceuticals Co Ltd
    • Vascular Biogenics Ltd
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
    • ApTLR-4FT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-1110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRX-526 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DMT-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDA-HPVE7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDA-NS3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDA-TRP2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDAGP-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Glyco-23 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-1795091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HE-3286 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hp-91 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISAS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JKB-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JKB-119 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JKB-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-16 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-MAPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEPA-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSCL-0520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSCL-0521 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TWJ-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Projects
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Featured News & Press Releases
    • Dec 09, 2016: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland
    • Dec 05, 2016: Immune Design Provides Update on Discovery Platform G100 For Intratumoral Immunotherapy
    • Nov 17, 2016: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study
    • Nov 10, 2016: MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
    • Oct 30, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland
    • Oct 11, 2016: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
    • Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients
    • Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
    • Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
    • Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO
    • May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
    • May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study
    • Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
    • Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
    • Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Batu Biologics Inc, H2 2016
  • Pipeline by BioLineRx Ltd, H2 2016
  • Pipeline by Biomedica Management Corp, H2 2016
  • Pipeline by eTheRNA Immunotherapies NV, H2 2016
  • Pipeline by Formune SL, H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by Harbor Therapeutics Inc, H2 2016
  • Pipeline by Immune Design Corp, H2 2016
  • Pipeline by Immunovo BV, H2 2016
  • Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
  • Pipeline by NovImmune SA, H2 2016
  • Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016
  • Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2016
  • Pipeline by Vascular Biogenics Ltd, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top